The long-term effects of placebo in patients with chronic schizophrenia

Biological Psychiatry

Volumn 46, Issue 8, 1999, Pages 1092-1105

  Wyatt, Richard Jed ^a   Henter, Ioline D ^a   Bartko, John J ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antipsychotic medications; Placebo; Schizophrenia

Indexed keywords

HALOPERIDOL; PLACEBO;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT OUTCOME;

BIOMEDICAL AND BEHAVIORAL RESEARCH; EMPIRICAL APPROACH; MENTAL HEALTH THERAPIES; NATIONAL INSTITUTE OF MENTAL HEALTH;

ADULT; ANTIPSYCHOTIC AGENTS; BIOETHICS; BRIEF PSYCHIATRIC RATING SCALE; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PLACEBO EFFECT; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS;

EID: 0032884605     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00227-9     Document Type: Conference Paper

References (48)

1. Diagnostic and Statistical Manual of Mental Disorders-III. 3rd edition. 1980;The American Psychiatric Association, Washington, DC.
2. Diagnostic and Statistical Manual of Mental Disorders-III-R. 3rd edition revised. 1987;The American Psychiatric Association, Washington, DC.
3. Angst J. European long-term followup studies of schizophrenia. Schizophr Bull. 14:1988;501-513.
4. Applebaum P. Rethinking the conduct of psychiatric research. Arch Gen Psychiatry. 54:1997;117-120.
5. Applebaum P.S. Drug-free research in schizophrenia an overview of the controversy . IRB. 18:1996;1-5.
6. Bailey B.J.R. Tables of the Bonferroni t statistic. J Am Statistical Assoc. 72:1977;469-478.
7. Bartko J., Carpenter W. On methods and theory of reliability. J Nerv Ment Dis. 163:1976;307-317.
8. Berg J.W., Applebaum P.S. Subjects' capacity to consent to neurobiological research. Pincus H.A., Lieberman J.A., Ferris S. Ethics in Psychiatric Research A Resource Manual for Human Subjects Protection . 1999;81-106 American Psychiatric Press, Washington, DC.
9. Bigelow L.B., Berthot B.D. The Psychiatric Symptom Assessment Scale (PSAS). Psychopharmacol Bull. 25:1989;168-179.
10. Bleuler M (1978): The Schizophrenic Disorders: Long-Term Patient and Family Studies [Clemens SM, trans]. New Haven: Yale University Press.
11. Carpenter W.T.J. The risk of medication-free research. Schizophr Bull. 23:1997;11-18.
12. Carpenter W.T.J., Schooler N.R., Kane J.M. The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry. 54:1997;401-407.
13. Ciompi L. The natural history of schizophrenia in the long term. Br J Psychiatry. 136:1980;420-423.
14. DeLisi L.E., Sakuma M., Tew W., Kushner M., Hoff A.L., Grimson R. Schizophrenia as a chronic active brain process A study of progressive brain structural change subsequent to the onset of schizophrenia . Psychiatry Res. 74:1997;129-140.
15. DeRenzo E.G., Conley R., Love R. Assessment of capacity to give consent to research participation State of the art and beyond . J Health Care Law Policy. 1:1998;66-87.
16. Fletcher J., Wichman A. A new consent policy for research with impaired human subjects. Psychopharmacol Bull. 23:1987;382-385.
17. Fleischhacker W.W. Clozapine a comparison with other novel antipsychotics . J Clin Psychiatry. 60:(Suppl 12):1999;30-34.
18. Flynn L., Honberg R. Achieving proper balance in research with decisionally-incapacitated subjects NAMI's perspective on the working group's proposal . J Health Care Law Policy. 1:1998;174-192.
19. Garver D.L., Kelly K., Fried K.A., Magnusson M., Hirschowitz J. Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias). Psychol Med. 18:1988;873-885.
20. Glovinsky D., Kirch D.G., Wyatt R.J., et al. Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry. 31:1992;968-970.
21. Grisso T., Applebaum P.S. Assessing Competence to Consent to Treatment A Guide for Physicians and Other Health Professionals . 1998;Oxford University Press, New York.
22. Hall L.L., Flynn L. Consumer and family concerns about research involving human subjects. Pincus H.A., Lieberman J.A., Ferris S. Ethics in Psychiatric Research A Resource Manual for Human Subjects Protection . 1999;219-238 American Psychiatric Association, Washington DC.
23. Harrow M., Sands J.R., Silverstein M.L., Goldberg J.F. Course and outcome for schizophrenia versus other psychotic patients a longitudinal study . Schizophr Bull. 23:1997;287-303.
24. Hyde T.M., Nawroz S., Goldberg T.E., et al. Is there cognitive decline in schizophrenia? A cross-sectional study. Br J Psychiatry. 164:1994;494-500.
25. Iskedjian M., Hux M., Remington G.J. The Canadian experience with risperidone for the treatment of schizophrenia an overview . J Psychiatry Neurosci. 23:1998;229-239.
26. Jeste D.V., Wyatt R.J. Understanding and Treating Tardive Dyskinesia. 1982;Guilford Press, New York.
27. Johnson D.A.W., Pasterski G., Ludlow J.M., Street K., Taylor R.D.W. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients Drug and social consequences . Acta Psychiatr Scand. 67:1983;339-352.
28. Kane J., Honigfeld G., SInger J. Clozapine for the treatment-resistent schizophrenic A double-blind comparison with chlorpromazine . Arch Gen Psychiatry. 45:1988;789-796.
29. Keck P.E., Cohen B.M., Baldessarini R.J., McElroy S.L. Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry. 146:1989;1289-1292.
30. Kraepelin E (1971): Dementia Praecox and Paraphrenia (1919) [Barclay RM, trans]. Huntington, NY: Robert E. Krieger.
31. Larsen T.K., Johannessen J.O., Opjordsmoen S. First-episode schizophrenia with long duration of untreated psychosis pathways to care . Br J Psychiatry. 172:(Suppl 33):1998;45-52.
32. Lieberman J., Jody D., Geisler S., et al. Time course and biological correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 50:1993;369-376.
33. Lieberman J.A. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry. 54:1993;13-17.
34. May P.R.A., Goldberg S.C. Prediction of schizophrenic patients' response to pharmacotherapy. Lipton M.A., DiMascio A., Killam K.F. Psychopharmacology A Generation of Progress . 1978;1139-1153 Raven Press, New York.
35. McGlashan T.H. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull. 14:1988;515-542.
36. Research involving persons with mental disorders that may affect decisionmaking capacity, Volume 1. Report and recommendations of the National Bioethics Advisory Commission. 1998;National Bioethics Advisory Commission, Washington DC.
37. Nedopil N., Ruther E. Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatria. 14:1981;205-207.
38. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol Res. 25:1962;168-179.
39. Palmer D., Henter I., Wyatt R.J. Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? J Clin Psychiatry. 60:(Suppl 2):1999;100-103.
40. Power P., Elkins K., Adlard S., Curry C., McGorry P., Harrigan S. Analysis of the initial treatment phase in first-episode psychosis. Br J Psychiatry. 172:(Suppl 33):1998;71-76.
41. Sautter F., McDermott B., Garver D. Familial differences between rapid neuroleptic response psychosis and delayed neuroleptic response psychosis. Biol Psychiatry. 33:1993;15-21.
42. Stern R.G., Kahn R.S., Davidson M. Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am. 16:1993;313-338.
43. Szymanski S., Lieberman J.A., Alvir J.M., et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry. 152:1995;698-703.
44. Watt D.C., Katz K., Shepherd M. The natural history of schizophrenia A 5-year prospective follow-up of a representative sample of schizophrenics by means of standardized clinical and social assessment . Psychol Med. 13:1983;663-670.
45. Wyatt R.J. Antipsychotic medication and the long-term course of schizophrenia therapeutic and theoretical implications . Shriqui C., Nasrallah H. Contemporary Issues in the Treatment of Schizophrenia. 1995;385-410 American Psychiatric Press, Washington, DC.
46. Wyatt R.J. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull. 23:1997;3-9.
47. Wyatt R.J. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 17:1991;325-351.
48. Wyatt R.J., Henter I. The effects of sustained intervention on the long-term morbidity of schizophrenia. J Psychiatr Res. 32:1998;169-177.